Seaport Therapeutics presents Phase 1 data showing 6.8‑fold higher bioavailability for GlyphAgo
Seaport Therapeutics disclosed Phase 1 pharmacokinetic results for its agomelatine prodrug GlyphAgo at the ECNP Congress in Munich. The study, which involved 174 healthy volunteers, demonstrated a 6.8‑times increase in agomelatine exposure and roughly ten‑fold lower variability versus the unmodified drug. The company has begun a Phase 2a trial in adults with generalized anxiety disorder and sleep disturbance, with topline data expected in early 2028, and plans a Phase 2/3 trial in the first half of 2027.
Why it matters
The company says the Phase 2a topline results expected in early 2028 will inform the design of the upcoming Phase 2/3 study and could reduce perceived liver‑safety risks, potentially improving the drug’s market prospects.
Key facts
- 1GlyphAgo achieved a 6.8‑fold increase in agomelatine bioavailability compared with unmodified agomelatine. investing.com
- 2Pharmacokinetic variability for GlyphAgo was about ten‑fold lower than for unmodified agomelatine. finanznachrichten.de
- 3The Phase 1 program enrolled 174 healthy volunteers. investing.com
- 4Seaport has started a Phase 2a trial in adults with generalized anxiety disorder and sleep disturbance. investing.com
- 5Topline results from the Phase 2a trial are expected in early 2028. investing.com
- 6A Phase 2/3 trial is planned for the first half of 2027. tradingview.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.